News

The agreement establishes the collaboration and structure to enable better scientific understanding of the medicinal use of cannabis to treat diseases such as Parkinson’s, epilepsy, Alzheimer’s, brain damage,

The expanded agreements will allow Gilead’s India-based partners to manufacture GS-5816 and the single tablet regimen of sofosbuvir/GS-5816, once approved, for distribution in 91 developing countries, which together

Ajinomoto Pharmaceuticals holds the manufacturing and marketing authorization rights to LIVAMIN Oral Granules. Under a basic contract concerning the marketing rights of LIVAMIN Oral Granules in the Asia

MPS IIIB is caused by a decrease in alpha-N-acetyl-glucosaminidase (NAGLU) enzyme activity which leads to the buildup of abnormal amounts of heparan sulfate (HS) in the brain and

The US Food and Drug Administration (FDA) also granted orphan drug designation for ApoCell). Enlivex, a Hadasit Bio-Holdings portfolio company, intends to commence a Phase IIb / III

The open-label, randomized, controlled, global pivotal trial is enrolling patients with advanced primary, not yet treated, head and neck cancer. The trial’s main objective is to show a

OPN-305 is a new humanized IgG4 monoclonal antibody (MAb) against the Toll-Like Receptor 2 (TLR2), a target within the innate immune system. Evaluation of OPN-305 in MDS will

The company acquired Sivextro, as a part of its purchase through a subsidiary of Cubist Pharmaceuticals. Sivextro is a once-daily oxazolidinone antibiotic developed for both intravenous and oral

Alirocumab is an investigational monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). Under the Prescription Drug User Fee Act (PDUFA), the goal for a priority review is